Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. grew its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 68.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,204 shares of the life sciences company's stock after purchasing an additional 24,043 shares during the period. Daiwa Securities Group Inc.'s holdings in Illumina were worth $8,244,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ILMN. Brown Brothers Harriman & Co. boosted its holdings in Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company's stock valued at $45,000 after purchasing an additional 106 shares in the last quarter. State of Wyoming acquired a new position in Illumina during the second quarter worth $32,000. Penserra Capital Management LLC acquired a new position in Illumina during the first quarter worth $64,000. Annis Gardner Whiting Capital Advisors LLC purchased a new position in Illumina in the third quarter worth $30,000. Finally, VisionPoint Advisory Group LLC raised its position in Illumina by 344.6% in the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company's stock worth $34,000 after acquiring an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insiders Place Their Bets

In other news, CEO Jacob Thaysen bought 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares of the company's stock, valued at $2,010,544.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by insiders.

Illumina Trading Up 0.6 %

NASDAQ ILMN traded up $0.74 during trading hours on Friday, hitting $117.43. 1,417,804 shares of the company's stock were exchanged, compared to its average volume of 1,759,154. The business's 50 day moving average is $133.78 and its 200-day moving average is $128.07. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.29 and a current ratio of 1.66. Illumina, Inc. has a 12-month low of $89.00 and a 12-month high of $229.58. The firm has a market capitalization of $18.70 billion, a P/E ratio of -16.03 and a beta of 1.19.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.13. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the company posted $0.14 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Stephens reaffirmed an "overweight" rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, April 10th. TD Cowen cut shares of Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 target price for the company. in a report on Thursday, January 4th. StockNews.com raised Illumina from a "hold" rating to a "buy" rating in a research note on Friday, February 16th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $253.00 price objective on shares of Illumina in a research note on Tuesday, April 9th. Finally, Barclays lifted their price objective on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a report on Wednesday, April 10th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Illumina presently has a consensus rating of "Hold" and an average price target of $167.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.